Provectus Bio (PVCT): Advancing Therapies to Treat Solid Tumor Cancers

Source: Equities, October 2016

Provectus Biopharmaceuticals (PVCT) is advancing therapies to treat solid tumor cancers and inflammatory dermatoses.

The company’s unique oncology compound PV-10 is a solution of small molecules and halogenated xanthene Rose Bengal, a proven treatment that has been used for over 100 years. The injection is designed to target only diseased cells and is potentially agnostic to other disease treatments. As mentioned above, PV-10 can be used in oncology or dermatology.

In Provectus’ tests (done in collaboration with Moffett Cancer Research Center) injections of PV-10 reduced even non-injected tumors. This is exciting and fights against metastasis of tumors, which is the silent killer. The compound also continued to strengthen the immune system after the treatment.